Charles Landen, MD
Gynecologic Oncology · Charlottesville, VANPI 1043384282
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,640 of the $3,103 with a category attached, or 85.1%. Genentech, Inc. accounts for 85.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2020 at $2,640 and has fallen 93.3% since, to $177 in 2023.
Across 9 payments — averaging $344.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$3K
- AstraZeneca$288
- Medtronic$55
- Eisai Inc.$49
- Roche Products Limited$38
- Johnson & Johnson$34
Across 31 payments — averaging $9804.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$128K
- Genentech, Inc.$118K
- Boston Scientific$57K
- F. Hoffmann-la Roche AG$461
What the payments were for
- Consulting fees$2,64085%
- Food & beverage$41513%
- Education$492%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 1 | $2,640 |
| AstraZeneca | 3 | $288 |
| Medtronic | 1 | $55 |
| Eisai Inc. | 1 | $49 |
| Roche Products Limited | 1 | $38 |
| Johnson & Johnson | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,103 in reported general payments places this provider in the 60th percentile of 47 gynecologic oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Megestrol Acetate | 13 | $936 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Charlottesville
- Samantha BatmanCharlottesville$76K
- Linda DuskaCharlottesville$72K
- Marilyn HuangCharlottesville$39K
- Kari RingCharlottesville$14K
- Susan ModesittCharlottesville$4K
- Leigh CantrellCharlottesville$460
- Jaime KiffCharlottesville$82
- Cecelia BoardmanRichmond$577K
- Leslie RandallFairfax$342K
- Chad HamiltonAnnandale$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.